Ongoing collapse of coral reef shark populations
Investigators have revealed that coral reef shark populations are in the midst of rapid decline, and that “no-take zones”—reefs where fishing is prohibited—do protect sharks, but only when compliance with no-take regulations is high. The findings, reported by William Robbins and colleagues at James Cook University and its ARC Centre of Excellence for Coral Reef Studies, appear in the December 5th...
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer
WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...
Advanced Viral Research Corp. Announces Positive Preliminary
Findings from Ongoing Phase II Dermatological Study
YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ViralResearch Corp. (OTCBB: ADVR), a research based biopharmaceuticalcompany, announced today that preliminary findings from its
ongoingPhase II dermatological study show topical treatment with AVR118appears to have clinical activity in reducing inflammation andredness associated with surgical incisions or dermatologicdermabrasion....
Novelos Therapeutics Announces Encouraging Results in Ongoing Phase
2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - NovelosTherapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical companyfocused on the development of therapeutics to treat cancer andhepatitis, today announced encouraging results in an
ongoingDana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002in combination with carboplatin in platinum-resistant ovariancancer patients. To date, 10...
Columbia Laboratories Reports Preliminary Findings from the Ongoing
Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%
(progesterone gel) to Prevent Preterm Birth
LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the
ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...